Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dyadic International, Inc. (DYAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.7043-0.1757 (-4.53%)
At close: 1:00PM EST
4.1000 +0.40 (+10.68%)
After hours: 04:34PM EST
Advertisement

Dyadic International, Inc.

140 Intracoastal Pointe Drive
Suite 404
Jupiter, FL 33477-5094
United States
561 743 8333
http://www.dyadic.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark A. EmalfarbFounder, CEO, Pres & Director724.29kN/A1956
Ms. Ping Wang RawsonChief Financial Officer301.09kN/A1976
Mr. Matthew S. JonesManaging Director of Bus. Devel. & Licensing365.32kN/A1978
Dr. Ronen TcheletVP of Research & Bus. Devel.259.92kN/A1958
Mr. Joseph P. HazeltonChief Bus. OfficerN/AN/AN/A
Ms. Ana Gómez RodriguezSec. of the BoardN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.

Corporate Governance

Dyadic International, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement